A 62-year-old woman from Delhi presents with acute onset chest pain and dyspnea for 3 hours. ECG shows ST elevation in leads V1–V4 (anterior STEMI). She underwent a cesarean section 4 days ago for her daughter's delivery (she was the surrogate). Troponin I is 3.2 ng/mL. The PCI lab is occupied with another emergency case and will be available in 90 minutes. She has no other contraindications to thrombolysis. Which of the following is the most appropriate management?

Question

Accepted Answer

A. Administer alteplase 15 mg bolus followed by weight-based infusion immediately. ## Clinical Context & Contraindication Analysis

This patient has acute anterior STEMI (high-risk territory with large myocardial mass at risk) presenting within 3 hours of symptom onset. However, **recent surgery (cesarean section 4 days ago) is a relative contraindication to streptokinase** due to increased risk of surgical site bleeding and intracranial hemorrhage.

**Key Point:** When streptokinase is contraindicated or high-risk, fibrin-selective thrombolytics (alteplase, reteplase, tenecteplase) are preferred because they have lower systemic fibrinogenolysis and reduced bleeding risk in perioperative patients.

## Thrombolytic Selection in Perioperative STEMI

| Agent | Fibrin Selectivity | Bleeding Risk (Post-Op) | Recommendation | Dosing |
|-------|-------------------|------------------------|-----------------|--------|
| Streptokinase | Low | **HIGH** (surgical site bleed, ICH) | **Contraindicated** | — |
| Alteplase | High | **LOW** (fibrin-selective) | **Preferred** | 15 mg IV bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg over 60 min (max 100 mg) |
| Reteplase | High | **LOW** | Acceptable alternative | 10 units IV bolus × 2, 30 min apart |
| Tenecteplase | Highest | **LOWEST** | Excellent choice (single bolus) | Weight-based: 30–50 mg IV bolus |

**High-Yield:** Fibrin-selective agents (alteplase, reteplase, tenecteplase) are the agents of choice in perioperative STEMI because they:
1. Preferentially lyse clot-bound fibrin (not circulating fibrinogen).
2. Preserve hemostasis at surgical sites.
3. Have lower intracranial hemorrhage (ICH) rates.

## Why Alteplase is Optimal Here

1. **Fibrin-selective:** Minimizes systemic fibrinogenolysis and surgical site bleeding.
2. **Proven efficacy:** GUSTO-I and TIMI-10B trials show superior 30-day mortality vs. streptokinase (~6.3% vs. 7.3%).
3. **Guideline-recommended:** ACC/AHA and ESC guidelines recommend fibrin-selective agents when streptokinase is contraindicated.
4. **Anterior STEMI:** High-risk territory; superior reperfusion rate (70–80%) is beneficial.
5. **Time-sensitive:** PCI will be available in 90 minutes, but door-to-needle thrombolysis should not be delayed; alteplase can be initiated immediately, and rescue PCI performed if reperfusion fails.

## Dosing: Alteplase for STEMI

**Weight-based protocol (accelerated infusion):**
- **Bolus:** 15 mg IV over 1–2 minutes
- **Infusion phase 1:** 0.75 mg/kg (max 50 mg) IV over 30 minutes
- **Infusion phase 2:** 0.5 mg/kg (max 35 mg) IV over 60 minutes
- **Total dose:** Not to exceed 100 mg

For this 62-year-old woman (assume ~60 kg):
- Bolus: 15 mg
- Phase 1: 45 mg over 30 min
- Phase 2: 30 mg over 60 min

**Clinical Pearl:** Anterior STEMI has the highest mortality (10–15% in-hospital) due to large myocardial territory at risk. Rapid reperfusion with a potent fibrin-selective agent is critical. Do NOT delay thrombolysis waiting for PCI if it will take >120 minutes from symptom onset.

## Bleeding Risk Mitigation

1. **Anticoagulation:** Enoxaparin 30 mg IV bolus, then 1 mg/kg SC q12h (preferred over unfractionated heparin in fibrinolysis).
2. **Antiplatelet:** Aspirin 300 mg (chewed) + clopidogrel 600 mg loading dose.
3. **Monitoring:** Watch for:
   - Surgical site bleeding (most common with SK; rare with alteplase)
   - Intracranial hemorrhage (ICH) — ~0.7% with alteplase vs. 1.1% with SK
   - Gingival bleeding, hematuria
4. **Rescue PCI:** If no reperfusion signs at 60–90 minutes, proceed to PCI (alteplase does not preclude PCI).

**Warning:** Do NOT withhold thrombolysis in perioperative STEMI just to "avoid bleeding." The mortality benefit of early reperfusion outweighs the bleeding risk if a fibrin-selective agent is used. Streptokinase, however, carries unacceptably high surgical site bleeding risk and should be avoided.

**Mnemonic: Perioperative STEMI Thrombolytic Choice — "SAFE"**
- **S**treptokinase = Avoid (high surgical bleed risk)
- **A**lteplase = Preferred (fibrin-selective, proven safe post-op)
- **F**ibrin-selective agents = First-line
- **E**arly reperfusion = Do not delay

Answer

B. Administer reteplase 10 units IV bolus immediately; repeat after 30 minutes if needed

Answer

C. Administer streptokinase 1.5 million units IV immediately; do not delay for PCI

Answer

D. Defer thrombolysis and wait for PCI availability in 90 minutes to avoid bleeding complications

Explanation

Practice similar questions